Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,626 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natural Selection Signatures in the Hondo and Ryukyu Japanese Subpopulations.
Liu X, Matsunami M, Horikoshi M, Ito S, Ishikawa Y, Suzuki K, Momozawa Y, Niida S, Kimura R, Ozaki K, Maeda S, Imamura M, Terao C. Liu X, et al. Among authors: suzuki k. Mol Biol Evol. 2023 Oct 4;40(10):msad231. doi: 10.1093/molbev/msad231. Mol Biol Evol. 2023. PMID: 37903429 Free PMC article.
C6 reference typing report.
Tokunaga K, Jin F, Mauff G, Nishimukai H, Simeoni E, Suzuki K, Weber W. Tokunaga K, et al. Among authors: suzuki k. Complement Inflamm. 1990;7(4-6):234-9. doi: 10.1159/000463153. Complement Inflamm. 1990. PMID: 2088658
The PRIMED Consortium: Reducing disparities in polygenic risk assessment.
Kullo IJ, Conomos MP, Nelson SC, Adebamowo SN, Choudhury A, Conti D, Fullerton SM, Gogarten SM, Heavner B, Hornsby WE, Kenny EE, Khan A, Khera AV, Li Y, Martin I, Mercader JM, Ng M, Raffield LM, Reiner A, Rowley R, Schaid D, Stilp A, Wiley K, Wilson R, Witte JS, Natarajan P; Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium. Kullo IJ, et al. Am J Hum Genet. 2024 Nov 14:S0002-9297(24)00379-3. doi: 10.1016/j.ajhg.2024.10.010. Online ahead of print. Am J Hum Genet. 2024. PMID: 39561770 Review.
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).
Suzuki K, Yokokawa T, Kawaguchi T, Takada S, Tamaki S, Kawasaki Y, Yamaguchi T, Koizumi K, Matsumoto T, Sakata Y, Arakawa Y, Ayuhara H, Hosonaga M, Yamaguchi M, Tsuji D. Suzuki K, et al. Sci Rep. 2024 Nov 16;14(1):28271. doi: 10.1038/s41598-024-79781-6. Sci Rep. 2024. PMID: 39550497 Free PMC article. Clinical Trial.
19,626 results
You have reached the last available page of results. Please see the User Guide for more information.